Natera Inc. has announced the results of a colorectal cancer study involving its tissue-free Latitude™ MRD assay. The data, presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI), highlight the assay's clinical performance in a cohort of approximately 200 patients with resectable stage I-IV colorectal cancer. This study, part of the GALAXY arm of the CIRCULATE-Japan study, demonstrates the assay's excellent clinical sensitivity to recurrence and high specificity. The assay detected recurrence with 58% sensitivity in the post-surgical MRD window and 81% sensitivity in the surveillance setting, with a median diagnostic lead time of 4.6 months. In the surveillance setting, patient-level specificity was reported at 92%, and sample-level specificity at 97%. Furthermore, MRD positivity was significantly associated with inferior outcomes, and the assay was predictive of adjuvant chemotherapy benefit among high-risk stage II and III patients who were MRD-positive post-surgery.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250707280681) on July 07, 2025, and is solely responsible for the information contained therein.
Comments